Timeline: COVID-19 Vaccines and Myocarditis
2020
The date is September 22, 2020. Myocarditis is classified as an adverse event of special interest, or a potential side effect, by the Centers for Disease Control and Prevention (CDC).
Oct. 30, 2020: U.S. Myocarditis is classified as a serious adverse event by the Food and Drug Administration (FDA).
One case of pericarditis is reported to the US in December 2020. The CDC and FDA jointly manage the Vaccine Adverse Event Reporting System (VAERS).
2020
The date is September 22, 2020. Myocarditis is classified as an adverse event of special interest, or a potential side effect, by the Centers for Disease Control and Prevention (CDC).
Oct. 30, 2020: U.S. Myocarditis is classified as a serious adverse event by the Food and Drug Administration (FDA).
One case of pericarditis is reported to the US in December 2020. The CDC and FDA jointly manage the Vaccine Adverse Event Reporting System (VAERS).
28 cases of myocarditis, pericarditis, or myopericarditis were reported to VAERS in January 2021.
According to a study published months later, the first U.S. military member suffers from postvaccination myocarditis in January 2021.
In Israel, the first cases of postvaccination myocarditis are reported in January 2021.
VAERS report processing is delayed in January 2021 due to an unexpected spike in reports.
In February 2021, VAERS received 64 reports of myocarditis, pericarditis, or myopericarditis, including two deaths.
Doctors say an Israeli teenager was hospitalized with myocarditis after receiving a Pfizer vaccination on February 1, 2021.
On February 18, 2021, a safety signal for myocarditis is generated in VAERS using a CDC-approved method known as Proportional Reporting Ratio.
On February 19, 2021, a safety signal for myocarditis is generated in VAERS using a different method known as Fisher’s Exact Test.
The CDC meets with its advisers on February 24-25, 2021, but does not discuss COVID-19 vaccines.
The FDA approves Johnson & Johnson’s COVID-19 vaccine on February 27, 2021.
On February 28, 2021, Israeli officials privately notify the CDC of “a large number of reports of myocarditis, particularly among young people, following administration of the Pfizer vaccine.”
On February 28, 2021, Israeli officials privately notify the European Medicines Agency of the cases of post-vaccination myocarditis.
On February 28, 2021, 57 cases of myocarditis or pericarditis occurred within seven days of vaccination in Pfizer’s database, according to a document given to the FDA in April 2021 but not made public until November 2021.
In March 2021, VAERS received 54 reports of myocarditis, pericarditis, or myopericarditis.
Emails show that on March 1, 2021, the UK Medicines and Healthcare Products Regulatory Agency identified myocarditis as a safety signal for COVID-19 vaccines.
The International Coalition of Medicines Regulatory Authorities, which includes the UK agency and the FDA, meets in private on March 1, 2021, to discuss the myocarditis issue.
March 1, 2021: CDC officials announce (pdf) the discovery of two postvaccination cases in the Vaccine Safety Datalink (VSD), another CDC-run system.
The CDC recommends Johnson & Johnson’s COVID-19 vaccine for adults on March 2, 2021.
March 3, 2021: A doctor notifies the CDC of a patient’s pericarditis as a result of a Pfizer vaccination.
Israeli authorities meet with hospital officials on March 3, 2021, to discuss postvaccination heart problems.
On March 4, 2021, Israeli officials confirm that they are looking into postvaccination pericarditis.
The FDA holds a meeting with its advisers on March 5, 2021. Myocarditis is not mentioned.
Rutgers University becomes the first major US university to announce a COVID-19 vaccine mandate on March 6, 2021.
Australian health officials contact the CDC about myocarditis cases in the United States on March 8, 2021.
March 9, 2021: According to a US internal memo, Israel received approximately 40 reports of postvaccination myocarditis. Officials in the United States say some postvaccination cases have been reported, and they acknowledge issues with passive surveillance, such as underreporting. “Thus, FDA has not made a final determination regarding the causality between myopericarditis and the mRNA COVID-19 vaccines,” the memo went on to say.
The first postvaccination myocarditis case report is published in the literature on March 20, 2021.
Pfizer contract with South Africa (pdf), March 20, 2021, states that “there may be adverse effects of the vaccine that are not currently known.”
The second postvaccination myocarditis case report is published on March 31, 2021.
On March 31, 2021, Israel reports the first death from postvaccination myocarditis. The deceased was a previously healthy 22-year-old woman.
In April 2021, VAERS received 158 reports of myocarditis, pericarditis, or myopericarditis.
In April 2021, the CDC holds a series of public meetings with no mention of myocarditis.
According to a news outlet, Israel has received 84 reports of postvaccination myocarditis or pericarditis as of April 1, 2021.
On April 2, 2021, US military officials and the CDC will meet to discuss postvaccination myocarditis cases.
On April 5, 2021, Israeli officials brief the CDC on cases of postvaccination myocarditis.
Canada reports the first case of postvaccination pericarditis on April 5, 2021.
On April 7, 2021, the United States government issued a call to cover myocarditis cases reported in military members following vaccination.
On April 10, 2021, the CDC-funded Clinical Immunization Safety Assessment program reviewed cases of postvaccination myocarditis, according to an email.
On April 12, 2021, US military officials brief the CDC on cases of postvaccination myocarditis.
According to a CDC official, the US military has submitted manuscripts on myocarditis cases to two journals as of April 13, 2021.
Due to six cases of blood clotting, the CDC and FDA advise a pause in the administration of Johnson & Johnson’s vaccine on April 13, 2021.
On April 15, 2021, two otherwise healthy adults were hospitalized with chest pain and diagnosed with myocarditis following a Moderna vaccination, according to a CDC adviser.
On April 17, 2021, a CDC official informs an adviser that there have been reports of myocarditis following COVID-19 vaccination, “but we aren’t observing any clear indication of a safety signal.”
On April 20, 2021, the CDC reports three cases of myocarditis following a second Pfizer dose in Idaho.
The United States lifts the recommended pause on Johnson & Johnson’s vaccine on April 23, 2021.
The Israeli Ministry of Health report on postvaccination myocarditis identifies two deaths on April 23, 2021, according to Israeli media. The second victim was a previously fit 35-year-old man. According to the study, men aged 18 to 30 have a one in 20,000 chance of developing myocarditis. “It seems that these events can be a signal of a possible connection to the vaccine,” said the committee’s report. The findings were forwarded to the FDA.
Military.com reports that on April 26, 2021, US military officials are tracking 14 cases of myocarditis caused by messenger RNA vaccination.
Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention, says the CDC is “aware of” cases in the military on April 26, 2021. According to her, “we have not seen any reports of those” and “we have not seen a signal” in CDC databases.
April 27, 2021: CDC officials privately admit that VAERS report processing is “taking longer than usual.”
On April 27, 2021, the CDC reported 24 cases of myocarditis in VSD.
On April 27, 2021, a senior US military official warns that halting the administration of the Pfizer and Moderna vaccines “will have an adverse impact on US/CA vaccination rates.”
France detects a safety signal for postvaccination myocarditis on April 28, 2021.
The CDC director receives notes from a discussion with the military about myocarditis cases on April 28, 2021.
The first cases of pericarditis following COVID-19 vaccination were reported in the literature on April 29, 2021.
The FDA receives a Pfizer report on myocarditis cases in Pfizer’s database on April 30, 2021.
487 cases of myocarditis, pericarditis, or myopericarditis were reported to VAERS in May 2021, with four deaths.
In May 2021, the CDC forms a team to review medical records for cases of postvaccination myocarditis that have been reported.
The CDC meets with advisers on May 5, 2021, but does not discuss COVID-19 vaccines.
May 7, 2021: The European Medicines Agency announces that it has requested information from Pfizer regarding myocarditis following COVID-19 vaccination.
The FDA approves Pfizer’s COVID-19 vaccine for children aged 12 to 15 on May 10, 2021. Myocarditis is not mentioned.
Myocarditis is not discussed during a meeting on Pfizer’s COVID-19 vaccine on May 12, 2021. A CDC official, Dr. Tom Shimabukuro, gives a presentation on blood clotting after a Johnson & Johnson vaccination.
Dr. Walensky recommends Pfizer’s vaccine for virtually all children aged 12 to 15, based on advice from advisers, on May 12, 2021.
May 13, 2021: CDC officials are directed to direct questions about potential myocarditis cases to Drs. Shimabukuro and John Su.
May 13, 2021: In heavily redacted emails, the same officials discuss analyzing VAERS data for myocarditis using the Proportional Reporting Ratio. According to the agency, the analysis did not begin until 2022.
On May 13, 2021, a CDC adviser reports that “multiple people texting and email[ing] me with concerns” about myocarditis.
Children’s National in Washington, DC, registers two suspected cases on May 13, 2021.
On May 14, 2021, Dr. Shimabukuro is looking for “experts in myocarditis.”
May 16, 2021: In an email, a CDC official states, “we are hearing quite a lot about this now, and I don’t have a clear understanding of what is and has been done.”
May 17, 2021: According to a CDC workgroup, there have been “relatively few” reports of myocarditis following vaccination, and rates “have not differed from expected baseline rates.”
Dr. Shimabukuro meets with officials from the American Academy of Pediatrics on May 17, 2021, to “centralize our coordination” with outside groups.
Dr. Su claims that health care providers “aren’t reporting these cases to VAERS.”
May 17, 2021: According to Dr. Su, the “myocarditis thing” is “exploding.”
On May 18, 2021, states across the United States publicly report cases of myocarditis caused by COVID-19 vaccination.
May 18, 2021: The first case report of postvaccination myocarditis in an American is published.
May 19, 2021: The CDC informs state officials that it has been “closely monitoring” cases of myocarditis and pericarditis following COVID-19 vaccination and that they “can be serious.”
Officials at Connecticut Children’s Medical Center report three new cases of postvaccination myocarditis on May 20, 2021.
On May 20, 2021, CDC officials meet with doctors from pediatric hospitals to discuss myocarditis cases. The Epoch Times was provided with fully redacted meeting slides.
May 23, 2021: The American Heart Association declares that the benefits of COVID-19 vaccination “far outweigh the rare, possible risk of heart-related complications, including inflammation of the heart muscle” for everyone who qualifies.
Washington state discovers 27 cases of post-vaccination myocarditis/pericarditis in rapid assessment on May 24, 2021.
May 24, 2021: For the first time, a CDC workgroup acknowledges that the number of reports of postvaccination myocarditis to VAERS was higher than expected in those aged 16 to 24.
May 24, 2021: The French Society of Cardiology calls for vaccinating heart failure patients despite the possibility of a vaccine-myocarditis link.
May 24, 2021: A Massachusetts official requests “messaging” from the CDC on postvaccination myocarditis.
May 25, 2021: FDA adviser Dr. Paul Offit says of myocarditis and COVID-19 vaccines, “there’s every reason to think this isn’t a problem.”
The New Zealand Medicines and Medical Devices Safety Authority issues a safety signal for myocarditis and COVID-19 vaccines on May 26, 2021.
May 28, 2021: The CDC says to continue vaccinating everyone who is eligible, or nearly all Americans aged 12 and up.
May 28, 2021: A case series of young, previously healthy males hospitalized with postvaccination myocarditis reveals admissions as early as January 30, 2021.
May 28, 2021: The CDC announces that it will focus on reported cases among those aged 30 and under.
According to the CDC, nine cases of postvaccination myocarditis from one state were not reported to VAERS on May 28, 2021.
Brighton Collaboration issues case definition for myocarditis on May 30, 2021.
In June 2021, VAERS received 752 reports of myocarditis, pericarditis, or myopericarditis, with five deaths.
In June 2021, some experts begin urging US authorities to halt COVID-19 vaccinations of young, healthy people.
June 2, 2021: Israel declares that “there is some probability for a possible link between the second vaccine dose and the onset of myocarditis among young men aged 16 to 30” after researchers discover a one-in-3,000 to one-in-6,000 incidence among men aged 16 to 24.
On June 4, 2021, researchers in the United States report seven cases in healthy young males following Pfizer vaccination.
On June 10, 2021, the FDA reported 99 cases of myocarditis/pericarditis in its Biologics Effectiveness and Safety Initiative database, with 1,260 cases reported in Medicare claims data (pdf).
June 10, 2021: A CDC official says the agency is working to quickly follow up on reports of myocarditis following vaccination among people aged 30 and under. The majority of cases occur in young adults after a second dose.
Dr. Cody Meissner, an FDA adviser, says on June 10, 2021, “there’s a lack of alternative explanations” other than vaccination given the consistency across postvaccination cases.
“I think the myocarditis is something that needs to be looked at closely because we’re likely seeing the tip of the iceberg,” says Dr. Michael Kurilla of the United States on June 10, 2021. Another FDA adviser is the National Institutes of Health. Pfizer spokesperson tells news outlets on June 10, 2021, that “the benefit-risk profile of our vaccine remains positive.”
The European Medicines Agency announces an investigation into reports of myocarditis following COVID-19 vaccination on June 11, 2021.
June 23, 2021: The CDC’s safety committee concludes that evidence now points to a “likely association” between mRNA vaccination and myocarditis.
On June 23, 2021, the number of myocarditis cases in VSD reaches 75. According to VAERS reports, the CDC reports that the number of events was higher than expected after dose two in males aged 12 to 49 and females aged 12 to 29. Through June 11, 188 cases among children aged 12 to 17 were reported within 21 days of vaccination. According to CDC experts, data suggests that vaccines cause myocarditis.
The CDC estimates (pdf) that Pfizer’s vaccine will cause up to 69 myocarditis cases per million second doses while preventing 215 hospitalizations and two deaths in males aged 12 to 17.
The FDA adds warnings about “the suggested increased risks” of myocarditis and pericarditis to the labels of the Moderna and Pfizer vaccines on June 25, 2021.
On June 28, 2021, the US Department of Veteran Affairs announced that it had discovered more myocarditis cases than expected.
Military researchers report 22 previously healthy members developed myocarditis after receiving a messenger RNA vaccine on June 29, 2021. “The presentation pattern and clinical course suggest an association with an inflammatory response to vaccination,” according to the researchers. Hundreds of cases have been reported in the literature this month.
The Centers for Disease Control and Prevention (CDC) says that “the striking clinical similarities in the presentations of these patients, their recent vaccination with an mRNA-based COVID-19 vaccine, and the lack of any alternative etiologies for acute myocarditis suggest an association with immunization.”
Canada adds myocarditis and pericarditis risk information to Moderna and Pfizer vaccine labels on June 30, 2021.
364 cases of myocarditis, pericarditis, or myopericarditis were reported to VAERS in July 2021, with seven deaths.
Researchers report that between April 1, 2021, and June 21, 2021, 13 young males with postvaccination myocarditis were treated at a single hospital in Washington state.
On July 6, 2021, the CDC predicts dozens of cases of myocarditis for every million doses of vaccination, with 56 to 69 cases among 12- to 17-year-olds. However, the agency believes that the expected benefits outweigh the risks.
After identifying 221 cases following mRNA vaccination, the European Medicines Agency recommends listing myocarditis and pericarditis as side effects for the Pfizer and Moderna vaccines on July 9, 2021. Five of the patients were killed.
July 10, 2021: South Korean researchers report the death of a 22-year-old man from vaccine-induced myocarditis, the first such death in the literature.
On July 22, 2021, the CDC reported 282 cases of postvaccination myocarditis in people aged 18 to 29.
Pfizer informs the FDA of a “important identified risk” of myocarditis and pericarditis following vaccination on July 28, 2021, and discloses 17 deaths among the cases reported.
According to the CDC and FDA, data mining does not show a signal for myocarditis among adolescents aged 12 to 17.
Australian experts recommend that people be informed about the possibility of myocarditis and pericarditis following vaccination by July 31, 2021.
311 cases of myocarditis, pericarditis, or myopericarditis were reported to VAERS in August 2021, with seven deaths.
The UK delays recommending a second dose for 16- and 17-year-olds until August 4, 2021.
15 children were admitted to Boston Children’s Hospital with postvaccination myocarditis between May 1 and July 15, 2021, according to researchers.
Canada discovers a safety signal for postvaccination myocarditis on August 13, 2021.
U.S. researchers report the death of a 27-year-old man from myocarditis following COVID-19 vaccination on August 17, 2021. The autopsy was refused by the family. There were no non-vaccination causes identified.
On August 18, 2021, researchers in the United States report the death of a 42-year-old man with myocarditis as a result of Moderna vaccination. There were no other causes discovered.
Dr. Walensky and other US government officials call for the withdrawal of COVID-19 vaccine boosters due to waning effectiveness on August 18, 2021.
Pfizer reports to the EMA two deaths from myocarditis following Pfizer vaccination on August 19, 2021.
Dr. Walensky informed the UK of his preference for Pfizer over Moderna for adolescents on August 19, 2021.
On August 23, 2021, the FDA approves Pfizer’s vaccine for people aged 16 and up. In theory, approval has a higher bar than authorization. According to the agency, analyzing reported events “will not be sufficient to assess known serious risks of myocarditis and pericarditis.”
Excess myocarditis risk for vaccinated males aged 16 or 17 is “approaching 200 cases per million,” according to the FDA, based on data from the Optum health care claims database.
On August 24, 2021, South Korean authorities determine that a young man died of myocarditis following a Pfizer vaccination.
Pfizer reports one case of myocarditis and one case of pericarditis among vaccinated trial participants on August 30, 2021.
According to CDC official reports (pdf), of 742 VAERS reports that met the CDC case definition of myocarditis or myopericarditis after vaccination, 701 patients required hospitalization and 18 are still hospitalized. At the time of the report, 23% of patients whose cases were detailed in VAERS reports were not known to have recovered.
According to the CDC, the highest rate of reported myopericarditis cases within seven days of a shot was 71.5 cases per million second Pfizer doses among boys aged 16 or 17.
The CDC announces (pdf) plans to follow myocarditis patients in order to assess long-term outcomes on August 30, 2021.
Myocarditis and pericarditis cases in VSD increase to 115 by August 30, 2021, with some patients still experiencing symptoms, according to a CDC official (pdf).
According to CDC officials, the benefits of Pfizer’s vaccine continue to outweigh the risks as of August 30, 2021. They estimate that every million Pfizer shots administered to 16- to 17-year-olds will result in 73 cases of myocarditis while preventing more hospitalizations.
An independent safety panel determined that a woman who died in New Zealand after receiving a Pfizer vaccination died of myocarditis on August 30, 2021.
377 cases of myocarditis, pericarditis, or myopericarditis were reported to VAERS in September 2021, with 10 deaths.
Pfizer’s safety database contains 654 reports of myocarditis or pericarditis as of September 2, 2021. According to the company, there are 77 reports of myocarditis or myocarditis and pericarditis in Moderna’s safety database. Some patients, including a young man, died or were unable to recover.
According to the European Medicines Agency, a causal association between myocarditis/pericarditis and mRNA vaccines is “considered of at least a reasonable possibility” based on the reports and other data.
The CDC reports 67 myocarditis/pericarditis cases in VSD between the ages of 12 and 39 on September 3, 2021.
Healthy, young boys face a higher risk of cardiac events from vaccines than from COVID-19, according to US researchers.
September 9, 2021: U.S. President Joe Biden and his administration announce mandates for COVID-19 vaccines for tens of millions of Americans, including many young, healthy people.
After a spike in myocarditis cases, Hong Kong changes its recommendation from two Pfizer doses to one dose on September 15, 2021.
“A clear signal for vaccine associated myocarditis has emerged,” doctors in the United States report on September 21, 2021.
On September 22, 2021, a CDC official reports one case of myocarditis following a Pfizer booster. According to the CDC safety committee, it is impossible to determine the risk of rare side effects such as myocarditis after boosting.
V-safe does not collect information on myocarditis, a CDC official admits on September 22, 2021.
On September 22, 2021, the FDA approves a Pfizer booster for millions of Americans.
On September 23, 2021, CDC officials say they have no idea how many cases of myocarditis booster shots will occur. They anticipate up to 26 cases per million boosters in 18- to 29-year-olds, but they claim that more COVID-19 cases and hospitalizations will be avoided.
The CDC recommends Pfizer’s booster for certain populations on September 24, 2021.
On September 27, 2021, a New Zealand expert tells the CDC that delaying second doses for children “seems to make a lot of sense to me.”
September 28, 2021: A Pfizer vaccine may have “played a role” in the death of a 15-year-old California boy who died after receiving a shot, according to the medical examiner.
The CDC holds a meeting on non-COVID vaccines on September 29, 2021.
On September 30, 2021, the CDC falsely informs California officials that reports of postvaccination myocarditis will not be received until June 20, 2021.
321 cases of myocarditis, pericarditis, or myopericarditis were reported to VAERS in October 2021, with five deaths.
The identification of postvaccination myocarditis cases “does not change clinical decision-making,” according to the editors of JAMA Internal Medicine on October 4, 2021.
Norway, Finland, and Sweden suspend use of Moderna’s vaccine for younger people due to myocarditis risks on October 7, 2021.
Iceland suspends use of Moderna’s vaccine on October 8, 2021, due to heart inflammation.
The CDC director was briefed on how Nordic countries are limiting vaccination due to myocarditis on October 11, 2021.
On October 12, 2021, a secret United States government meeting to discuss counting post-infection immunity as one or more vaccine doses concludes with no update.
On October 14, 2021, the FDA announced that more cases of myocarditis/pericarditis had been reported to its Biologics Effectiveness and Safety Initiative system.
Oct. 21, 2021: The CDC publicly discloses that the US Department of Veterans Affairs has identified 7 cases of post-vaccination myocarditis, but no signal was established and all cases were resolved.
According to VAERS data, the highest rate of myocarditis following vaccination is 69.1 cases per million second shots among males aged 16 or 17, according to Dr. Su (pdf).
According to available data, approximately a quarter of cases in people 29 or younger reviewed in VAERS were not known to have recovered, with 19 still hospitalized.
Oct. 21, 2021: VSD data analyses “indicate that both Pfizer and Moderna are associated with an increased risk of myocarditis/pericarditis in 12-39-year-olds,” according to a Kaiser Permanente doctor (pdf). Cases of myocarditis/pericarditis in VSD increase to 138, with rates higher after Moderna vaccination versus Pfizer vaccination.
On October 21, 2021, the CDC recommends that tens of millions of Americans receive a Pfizer or Moderna booster.
According to French researchers, the rate of reported cases among males aged 18 to 24 is approximately 139 per million after the second dose of Moderna and 43 per million after the second dose of Pfizer.
Norway says adolescents cannot receive second doses of Pfizer’s vaccine after October 22, 2021.
On October 26, 2021, the FDA declares that the benefits of vaccination outweigh the risks. The risk is greatest for 16- and 17-year-old males, with 196 postvaccination myocarditis cases and 171 myocarditis/pericarditis hospitalizations per million doses.
Dr. Matthew Oster, a CDC cardiologist, says “we don’t know a whole lot” about myocarditis after COVID-19 vaccination on October 26, 2021. “We really need to see what the long-term outcomes for these kids will be,” he said at the time.
Dr. Michael Nelson, an FDA vaccine adviser, expressed concern on October 26, 2021, that some cases of postvaccination myocarditis were not being reported.
Dr. Eric Rubin, another FDA adviser, says on October 26, 2021, “we’re never going to learn about how safe this vaccine is unless we start giving it.”
The World Health Organization reports that mRNA vaccines are likely to cause myocarditis on October 27, 2021.
Researchers say the prevalence of postvaccination myocarditis may be underestimated due to its reliance on symptoms for diagnosis.
Dr. Su says myocarditis reported after COVID-19 vaccination “has been neither severe nor persistent… however, we’ll need to wait to see if longer-term complications arise.” He also says the CDC doesn’t know what percentage of cases became chronic.
Despite a lack of efficacy data, the FDA approves Pfizer’s vaccine for children aged 5 to 11 on October 29, 2021.
Researchers report (pdf) on 17 myocarditis patients seen at a single facility in Switzerland between March and July 2021.
The FDA postpones its decision on approving Moderna’s vaccine for children until October 31, 2021.
267 cases of myocarditis, pericarditis, or myopericarditis were reported to VAERS in November 2021, with six deaths.
Dr. Su writes in an email on November 1, 2021, that “we’re all doing our part to build confidence” in COVID-19 vaccines.
On November 1, 2021, English researchers estimate that vaccinating children aged 12 to 17 will prevent 230 to 4,590 COVID-19 hospitalizations while causing 160 cases of myocarditis that will necessitate hospitalization.
Seven patients with myocarditis still had symptoms a month after being diagnosed, according to researchers in the United States.
On November 2, 2021, nine deaths from myocarditis were reported in VAERS among people aged 29 and under. According to a CDC official (pdf), the majority of deaths had at least one potential non-vaccination cause, with the evaluation of two still ongoing.
According to an official, 72 percent of postvaccination myocarditis patients who received cardiac MRIs had abnormal results. 48 percent of patients who responded to the CDC survey said their symptoms persisted after three months.
The CDC reports that rates of myocarditis after Pfizer vaccination in children aged 5 to 11 are unknown as of November 2, 2021 (pdf). Males aged 12 to 15 have rates as high as 108.5 per million second doses.
On November 2, 2021, the CDC recommends that nearly all children aged 5 to 11 receive the Pfizer series.
On November 3, 2021, an 18-year-old previously healthy woman dies from fulminate myocarditis following a COVID-19 vaccination, according to Washington state officials. The myocarditis is attributed to asymptomatic COVID-19. The family declined an autopsy at one facility, and the King County Medical Examiner’s Office stated that no autopsy was performed due to “social and complex” reasons.
France suspends Moderna’s vaccine for people under the age of 30 on November 8, 2021.
On November 16, 2021, the United Kingdom recommends a second dose for 16- and 17-year-olds.
Nov. 18, 2021: Reported cases of myocarditis as high as 117 per million after Moderna doses and 47 per million after Pfizer doses among males aged 18 to 29, according to German researchers.
Nov. 19, 2021: Lower rates of myocarditis reported to VAERS following booster doses, according to a CDC official (pdf). Fifty-four reports were filed, with some people still missing.
On November 19, 2021, the CDC allows all adults to receive a booster dose of the Pfizer or Moderna vaccines.
Between December 27, 2020 and September 3, 2021, 113 patients with suspected myocarditis following COVID-19 vaccination presented to a single practice, according to German researchers.
Six people have died from myocarditis or pericarditis following a Pfizer vaccination, according to the Netherlands Pharmacovigilance Centre Lareb. Two of the deaths had other causes discovered.
On November 28, 2021, Hong Kong researchers discovered a rate of 212 myocarditis cases per million Pfizer second doses among 12- to 17-year-old males.
The CDC discloses three confirmed cases of post-booster myocarditis in private emails on November 28, 2021.
On November 29, 2021, the United Kingdom recommends a second dose for children aged 12 to 15.
In December 2021, VAERS received 304 reports of myocarditis, pericarditis, or myopericarditis, including five deaths.
On December 1, 2021, a 22-year-old woman was admitted to the hospital with myocarditis following an AstraZeneca vaccination, according to South Korean researchers.
The European Medicines Agency confirms a safety signal for postvaccination myocarditis on December 2, 2021.
On December 2, 2021, Israeli researchers predict 106.9 cases of myocarditis per million vaccinated males aged 16 to 29.
The FDA approves booster doses for 16- and 17-year-olds on December 9, 2021.
The CDC recommends that 16- and 17-year-olds get a booster shot on December 9, 2021. Myocarditis is not mentioned.
On December 14, 2021, 114 vaccinated people had myocarditis listed as a cause of death on their death certificates, according to English researchers.
On December 16, 2021, the CDC confirms eight cases of myocarditis in children aged 5 to 11, including one in a 6-year-old male.
An autopsy on December 18, 2021, determined that a 26-year-old New Zealand man died as a result of vaccine-induced myocarditis.
Males under the age of 40 face an increased risk of 101 cases per million second doses, according to UK researchers.
On December 27, 2021, researchers in the United States estimate that the incidence of myocarditis among males aged 12 to 39 is 195.4 per million second doses. They find cases that the CDC missed. The risk of myocarditis from Moderna’s vaccine is much higher than the risk from Pfizer’s shot, according to Canadian officials.
Dec. 30, 2021: Between December 15, 2020, and June 15, 2021, 21 patients with myocarditis following COVID-19 vaccination were admitted to a single center, according to US researchers.
Moroccan doctors say a 14-year-old boy was hospitalized with shock after receiving a Pfizer vaccination on December 30, 2021.
2022
Non-vaccine causes of death have been ruled out in the death of a 57-year-old New Zealand woman who developed myocarditis after receiving COVID-19 vaccination, according to researchers.
On January 5, 2022, 327 cases of myocarditis in children aged 12 to 15 were reported to VAERS, with some cases not known to have recovered, according to a CDC official (pdf). Males in the age group received 45.7 million second doses, while males aged 5 to 11 received 4.3 million second doses, both of which were higher than expected.
According to a VSD researcher, most confirmed myocarditis patients aged 12 to 17 in VSD were hospitalized, with more than a quarter being hospitalized for at least four days (pdf). Excess cases as high as 70.8 per million second doses in the age group within 21 days. During follow-up visits at least three months later, nearly half of the confirmed cases had new or worsening symptoms, and half had abnormal electrocardiogram results.
On January 5, 2022, the rate of myocarditis after Pfizer vaccination was reported to be as high as 153 per million second doses among males aged 16 to 19.
On January 11, 2022, a 26-year-old American man died from vaccine-induced myocarditis.
Rates of reported cases in the United Kingdom as high as 71 per million second Moderna doses among people aged 18 to 29 on January 19, 2022.
The CDC issued an alert on January 24, 2022, following the death of a male with autopsy-confirmed vaccine-induced myocarditis.
On January 25, 2022, the CDC reported rates of reported myocarditis cases of 70.7 per million second doses for males aged 12 to 15, and 105.8 per million second doses for males aged 16 and 17. The agency has verified 1,626 reports and believes that underreporting is likely.
On January 31, 2022, the FDA (pdf) approves Moderna’s vaccine for people aged 18 and up. The Food and Drug Administration (FDA) claims that case reports are “not sufficient to assess known serious risks of myocarditis and pericarditis and identify an unexpected serious risk of subclinical myocarditis.”
The death of a 24-year-old American man from vaccine-induced myocarditis is confirmed on February 3, 2022. The man’s family later sues the US government.
Moderna reports three cases of pericarditis among vaccinated trial participants on February 4, 2022 (pdf). Two cases, one in a 23-year-old man, were labeled as vaccine-related.
According to a CDC official, rates of reported VAERS myocarditis cases among 18- to 24-year-olds within seven days of vaccination could reach 40 per million second doses. The majority of patients were hospitalized and discharged, but 30% were not known to have recovered.
Excess cases of myocarditis in males up to 61.8 per million within seven days of second Moderna doses, according to VSD data.
Danish officials report to the CDC on February 4, 2022, that the risk of myocarditis is 9.8 times higher after a Moderna second dose among males aged 12 to 39 when compared to the unvaccinated.
Feb. 4, 2022: The CDC reports that nearly half of 360 people who had myocarditis and responded to a survey an average of 143 days later reported at least one symptom, such as chest pain, in the previous two weeks (pdf). According to patient providers, roughly four out of ten had physical activity restrictions months after the diagnosis.
Data now show a “association of myocarditis” with Moderna’s vaccine and young people, according to the CDC safety committee. The group says it will keep reviewing data on myocarditis after vaccination.
Lower rates of myocarditis were recorded when the interval between the two primary series doses was extended, Canadian researchers report to the CDC on February 4, 2022.
On February 4, 2022, the CDC predicts 68 cases of myocarditis for every million Moderna second doses and 47 cases for every million Pfizer second doses among males aged 18 to 39. According to the agency, more hospitalizations are expected to be avoided, with the benefits outweighing the risks. They rely on outdated effectiveness assumptions and VSD myocarditis rates.
Feb. 4, 2022: VSD researcher reveals that the definition of myocarditis cases has been expanded in response to feedback (pdf).
On February 9, 2022, the FDA declares that “the societal benefit of mass vaccination is overwhelming.”
On February 11, 2022, the FDA postpones a planned meeting to decide whether to approve Pfizer’s vaccine for babies and toddlers.
According to an internal Pfizer document dated February 11, 2022, “there is evidence that suggests patients who receive a COVID-19 vaccine are at an increased risk of myocarditis.”
On February 14, 2022, medical examiners in the United States report two deaths among minors from myocarditis caused by Pfizer vaccination.
Researchers report 21 patients with myocarditis after COVID-19 vaccination at a Canadian facility through November 2021.
On February 23, 2022, the CDC updates its guidance, advising people, including young males, to wait eight weeks between primary series doses.
On February 25, 2022, Hong Kong researchers report that one in 2,563 males aged 12 to 17 developed myocarditis following Pfizer vaccination.
Myocarditis rates in children aged 12 to 15 are higher among vaccinated versus unvaccinated, according to Israeli researchers.
“Vaccine-induced myocarditis should be considered in patients with acute symptom onset after mRNA vaccination,” German researchers say on March 10, 2022.
Five teenagers were found to have persistent heart injury 106 to 134 days after being diagnosed with myocarditis.
On March 18, 2022, a 17-year-old boy was admitted to the hospital with myocarditis following his second Pfizer dose, according to Japanese researchers.
On March 21, 2022, researchers in the United States estimate 450 myocarditis cases per million doses among males aged 12 to 17.
March 23, 2022: Heart scarring was discovered in seven of nine patients seven to eight months after myocarditis was diagnosed, according to Israeli doctors. Scarring has been linked to sudden death, and patients are advised to have annual checkups.
On March 25, 2022, the CDC performs the first Proportional Reporting Ratio analysis on VAERS data and detects safety signals for both the Moderna and Pfizer vaccines. The CDC falsely claimed that mining would begin in 2021, but later retracted the claim.
March 25, 2022: Many patients with three to eight months of followup had persistent abnormalities on cardiac MRIs, according to US researchers.
Ethics experts warn against vaccinating healthy children on March 25, 2022.
Officials in Israel report 213 cases of postvaccination myocarditis as of April 6, 2022.
COVID-19 poses a higher risk of myocarditis than vaccination, according to a non-peer-reviewed CDC study published on April 8, 2022.
Myocarditis meets a safety signal in VSD on April 20, 2022, according to a CDC panel (pdf). A review of medical records confirmed about half of the cases. Forty cases occurred following a booster in people aged 12 to 39, and another 34 occurred in those aged 40 and up.
April 20, 2022: The number of reported cases in VAERS rises to 148 within seven days of a booster, according to a CDC official. The highest rate among people aged 16 or 17 is 23.2 cases per million Pfizer booster doses. The majority of patients were admitted to the hospital, but they were all released.
April 20, 2022: New data “do not suggest additional safety concerns beyond those previously identified,” according to the CDC’s vaccine safety committee (pdf).
Reported cases in the United States on April 20, 2022. The Department of Veterans Affairs system now has 40 users; a chart review confirmed 15.
According to Nordic researchers, there could be up to 379 extra cases per million vaccinated males aged 16 to 24 on April 20, 2022.
On April 26, 2022, the FDA predicts that up to 196 excess myocarditis cases requiring hospitalization will be caused in males aged 16 or 17. In two of three scenarios, this number exceeds the number of COVID-19 hospitalizations avoided.
Late gadolinium enhancement (LGE) was found in 80 percent of myocarditis patients who had follow-up cardiac MRIs a median of 92 days after hospital discharge, according to researchers in the United States. LGE is linked to sudden death.
The CDC conducts the first Proportional Reporting Ratio analyses comparing the mRNA vaccines to other vaccines on VAERS data in May 2022, revealing a safety signal for myocarditis for both shots.
On May 3, 2022, one of 41 people in a prospective booster study was found to have subclinical pericarditis.
Scarring detected in follow-up cardiac MRIs, according to Canadian researchers.
May 5, 2022: The FDA restricts the use of a Johnson & Johnson vaccine due to concerns about blood clotting.
“There is no test or investigation that can establish causality for vaccine-associated myocarditis or pericarditis,” Canadian physicians say on May 6, 2022.
May 14, 2022: A study finds that the effectiveness of Pfizer vaccines in some children deteriorates over time.
On May 17, 2022, Hong Kong authorities decide to compensate the family of a 66-year-old woman who died of myocarditis following a Pfizer vaccination.
The CDC reports a postvaccination myocarditis death in a young boy on May 19, 2022. The Centers for Disease Control and Prevention acknowledges “rare reports” of postvaccination myocarditis deaths in other countries, but claims “it is unclear to what extent such cases were investigated.”
May 19, 2022: 64 cases of myocarditis after Pfizer vaccination reported in VAERS among children aged 5 to 11; 20 confirmed, according to the CDC (pdf). Another ten cases were reported in the age group in VSD, with six confirmed.
May 19, 2022: Reports of myocarditis as high as 74.2 per million within seven days of vaccination after a second dose of Pfizer’s vaccine among males aged 16 or 17. Male rates are 48.1 for those aged 12 to 15, and 35.3 for those aged 18 to 24.
May 19, 2022: As the CDC panel of advisers votes in favor of a Pfizer booster for children aged 5 to 11, adviser Veronica McNally advises parents that rates of myocarditis are lower after a booster and that the booster will increase protection.
June 7, 2022: A CDC official declares (pdf) that evidence supports a causal association between mRNA vaccines, the first time the CDC has made such a declaration.
The CDC reports that rates of myocarditis in males as young as 5 and as old as 49 are higher than expected. The number of confirmed cases that resulted in deaths has risen to 21, but according to the CDC, none of the deaths were caused by myocarditis.
June 7, 2022: According to a survey of health care providers who cared for patients, 18.3 percent had not fully recovered months later. According to available data, most people “recover from myocarditis within 3-8 months of diagnosis,” according to Dr. Shimabukuro, but “there may be long-term effects.”
Novavax reports five cases of myocarditis in vaccinated volunteers in its COVID-19 vaccine trials on June 7, 2022.
On June 11, 2022, 411 myocarditis cases were discovered in a health claims database that included CVS Health data, within seven days of COVID-19 vaccination.
According to a CDC official, rates of reported myocarditis following a booster shot are higher than expected in males aged 12 to 29 (pdf).
Myocarditis meets safety signal for children aged 12 to 17 after first and second doses in FDA’s BEST system, according to an FDA official (pdf).
On June 17, 2022, the FDA approves Pfizer and Moderna vaccines for children as young as six months old.
Researchers discovered that Hong Kong’s single-dose recommendation resulted in a decrease in myocarditis cases on June 17, 2022.
Heart failure and sudden death have been recorded following COVID-19 vaccination, according to Hong Kong researchers.
According to a CDC official, it is “difficult to know… what the myocarditis rates would be” among adolescents after increasing.
On June 23, 2022, the CDC reported nearly 1,000 cases of myocarditis among children aged 5 to 17 following Pfizer vaccination to VAERS (pdf). According to verified reports, rates as high as 75.9 per million among males aged 16 to 17 after a second Pfizer dose.
On June 23, 2022, 37 percent of patients whose health care providers responded to a CDC survey were not fully recovered 90 days after diagnosis.
Myocarditis meets safety signal criteria in VSD for boosters from Pfizer and Moderna, according to a CDC panel. Excess cases of 200.3 per million boosters among males aged 16 or 17, which is greater than the second dose rate. Many patients were admitted to the hospital, but they were all released.
Dr. Sarah Long, a CDC adviser, expresses surprise with the myocarditis rate following a booster on June 23, 2022.
On June 23, 2022, Moderna’s database contains over 1,000 myocarditis reports, according to a Moderna official (pdf).
According to a CDC official, patients who developed myocarditis after receiving a first dose, were vaccinated again, and developed myocarditis again.
Vaccinated people have a higher risk of serious adverse events of special interest, according to a reanalysis of clinical trial data.
On June 25, 2022, French researchers discover one case of myocarditis in 5,900 males aged 18 to 24 who receive a second Moderna dose.
On February 22, 2022, Australian doctors reported 75 cases of confirmed myocarditis following vaccination in adolescents aged 12 to 17.
July 3, 2022: A 27-year-old man died 28 days after losing consciousness during a sports practice and 36 days after receiving a Moderna vaccination, due to myocarditis, according to an autopsy.
July 4, 2022: A prospective study of 3,800 health care workers receiving a booster identifies two cases of myocarditis.
The FDA approves Novavax’s COVID-19 vaccine on July 13, 2022, despite evidence that the vaccine increased the risk of myocarditis and pericarditis.
July 14, 2022: 45 myocarditis events reported in children aged 5 to 11, some of which were confirmed, during the first four months of COVID-19 vaccine administration to this age group.
July 19, 2022: There are 1,321 confirmed VAERS myocarditis reports, with another 515 ruled out or under review. The highest rate continues to be 75.9 per million second doses administered to males aged 16 or 17. In 18- to 39-year-old males, the highest excess case rate in VSD is 62.8 per million Moderna second doses.
The CDC recommends Novavax’s vaccine for adults on July 19, 2022.
July 20, 2022: German doctors demand more autopsies on people who die from myocarditis after receiving the COVID-19 vaccine.
July 20, 2022: 41 cases of myocarditis, including one death, in adults following COVID-19 vaccination in the Kaiser Permanente health system through February 28, 2022.
Through September 30, 2021, 448 cases of myocarditis or pericarditis were identified in Italy as of July 28, 2022.
Excess myocarditis cases per million second doses in males aged 18 to 29 are estimated to be 162 and in males aged 39 to 39 to be 244, according to Canadian researchers.
On August 5, 2022, a CDC official admits to providing false information about the safety of the COVID-19 vaccine.
Thai researchers report that 29 percent of 301 school students experienced cardiovascular effects after Pfizer vaccination on August 8, 2022. “Adolescents receiving mRNA vaccines should be monitored for cardiovascular side effects,” the researchers say.
Moderna’s global safety database received 3,107 reports of myocarditis after vaccination between August 8, 2022 and February 15, 2022.
Data mining for the Moderna and Pfizer vaccines “didn’t really contribute to much of anything,” a CDC official privately admits.
On August 22, 2022, more than 2,800 hospital admissions for myocarditis were identified following COVID-19 vaccination, according to UK researchers.
On August 31, 2022, the FDA approves updated, bivalent Pfizer and Moderna vaccines as boosters for people aged 12 and up. Until now, the boosters had only been tested on animals.
The risk of myocarditis from bivalent COVID-19 boosters is “unknown,” according to a CDC official (pdf).
The CDC recommends that people aged 12 and up receive one of the new boosters beginning September 1, 2022.
According to a CDC official, there have been no reports of myocarditis in young children to VAERS as of September 1, 2022. Within seven days of a booster, males aged 12 to 29 had higher rates than expected, reaching 21.6 per million.
Sept. 1, 2022: Myocarditis rates in VSD as high as 189 per million for males aged 16 or 17, up from 137 per million after a second dose.
According to Israeli officials, the cases of postvaccination myocarditis “suggest a causal relationship” between the mRNA vaccines and heart inflammation.
The date is September 6, 2022. According to the military, Defense Secretary Lloyd Austin will not be alerted to myocarditis following a COVID-19 vaccination until May 25, 2021.
On September 23, 2022, most myocarditis patients had recovered at 60 to 180 days after diagnosis, though some had persistent symptoms, according to Hong Kong researchers.
Blood samples taken during and two to four days after the fourth vaccine dose revealed myocardial injury in two participants, according to a prospective study conducted in Israel.
CDC officials reveal that the rate of reported myocarditis cases in VAERS is higher after booster for young males than after second dose on October 4, 2022.
Due to an analysis of death certificates, Florida’s surgeon general recommends against mRNA COVID-19 vaccines for males aged 18 to 39 on October 7, 2022.
Oct. 15, 2022: Two of five adult myocarditis patients had persistent symptoms at least 57 days after their initial cardiac MRI, according to Minnesota researchers.
Myocarditis safety signal after Pfizer vaccination identified in people aged 12 to 64 in health claims surveillance system on October 26, 2022, according to FDA.
At a 12-week followup, six of nine myocarditis patients showed persistent heart injury, with one experiencing persistent symptoms, according to Italian researchers.
The CDC reports nine cases of myocarditis or pericarditis following bivalent vaccination on November 4, 2022.
On November 7, 2022, Canadian researchers predict a rate of myocarditis of 269.5 cases per million Moderna second doses and 58 cases per million Pfizer second doses in males aged 18 to 29.
LGE was still observed at followup in myocarditis patients in 2022, with two reporting persistent symptoms, according to German researchers.
On November 12, 2022, Italian researchers estimate that the number of Moderna doses required to harm is greater than the number of doses required to treat 16- to 19-year-old men.
Canadian researchers report 141 myocarditis cases in British Columbia within 21 days of COVID-19 vaccination through March 10, 2022.
Nov. 27, 2022: Autopsies of five Germans who died unexpectedly within 20 days of receiving a COVID-19 vaccination revealed myocarditis, with other possible causes ruled out.
On December 5, 2022, researchers in the United States estimate that for every COVID-19 hospitalization avoided by vaccine boosters, 1.5 to 4.6 cases of myocarditis would be caused in young males.
Researchers from the CDC and other institutions report clusters of myocarditis cases after the second Pfizer dose in the 12 to 39 age group in VSD on December 16, 2022.
The majority of studies on postvaccination myocarditis lacked proper stratification, according to a review published on December 28, 2022.
LGE was found in all seven myocarditis patients who had follow-up cardiac MRIs three to six months after diagnosis, according to Turkish researchers. Two patients experienced heart swelling.
Pfizer misses the deadline for a post-approval myocarditis study on December 31, 2022. The FDA later admits that it allowed Pfizer to postpone the deadline.
2023
Jan. 3, 2023: Eight sudden cardiac deaths in Qatar following COVID-19 vaccination were determined to be caused by the vaccination.
Blood analysis reveals “unbound” spike protein in plasma of people with myocarditis after vaccination on January 4, 2023.
Jan. 5, 2023: One percent of electrocardiograms in a prospective study of a second Pfizer dose in Taiwanese high school students return abnormal.
Jan. 5, 2023: The Portuguese Society of Cardiology declares “unequivocal” evidence linking the COVID-19 vaccines to myocarditis.
Jan. 9, 2023: An imaging study of five children conducted three to 109 days after the onset of myocarditis symptoms following a Pfizer vaccination reveals signs of heart scarring.
Jan. 26, 2023: FDA issues a safety signal for Pfizer’s updated vaccine for myocarditis and pericarditis in adults aged 18 to 35 (pdf).
On February 1, 2023, 530 people in Nordic countries were diagnosed with myocarditis as a result of mRNA vaccination, according to researchers. Six people died.
Taiwanese researchers estimate 126 myocarditis cases per million second doses among males aged 12 to 17 on February 8, 2023.
England stops giving booster shots to young, healthy people on February 13, 2023.
Feb. 14, 2023: 134 cases of heart failure and six cases of myocarditis among vaccinated people in 99 counties in 2021, according to a study of medical records.
On February 15, 2023, Australia discovered that myocarditis played a role in the death of a 21-year-old woman, according to newly disclosed documents.
Singapore says it will pay the family of a man who died of myocarditis after receiving the COVID-19 vaccine on February 22, 2023.
In its latest risk-benefit analysis (pdf), the CDC estimates a small number of myocarditis cases for every million boosters on February 24, 2023. Calculus is criticized by experts as flawed.
On February 24, 2023, a CDC official reports one case of myocarditis following bivalent vaccination in VSD.
According to a CDC official, the risk of myocarditis following a bivalent shot is unknown as of February 24, 2023.
On February 24, 2023, CDC officials provide misleading information about vaccine safety monitoring and refuse to correct the record.
Taiwanese authorities say the family of a young girl who died from myocarditis after receiving a Pfizer vaccination will be compensated on February 27, 2023.
March 3, 2023: The CDC discloses that plans for a collaboration to “stimulate VAERS reporting” from health care workers and long-term care facilities were never implemented.
Canadian researchers report persistent heart inflammation in three of 17 people after a two-month followup.
Pfizer’s bivalent is approved as a booster for children under the age of five by the FDA on March 14, 2023.
March 15, 2023: The FDA adds a warning about myocarditis to Johnson & Johnson’s vaccine fact sheets.
The CDC adds language to its website on March 17, 2023, stating that mRNA vaccines cause myocarditis.
A 14-year-old girl died of vaccine-related myocarditis on March 20, 2023, according to Japanese researchers.
March 22, 2023: Moderna CEO Stephane Bancel claims that after COVID-19 infection versus vaccination, all age groups are at a higher risk of myocarditis.
The World Health Organization estimates that additional boosters would provide a “marginal” benefit to healthy children and young adults by March 30, 2023.
Hong Kong researchers report that extending the interval between primary series doses reduced the incidence of myocarditis.
South Korean researchers report 173 cases of postvaccination myocarditis among children between July 19, 2021 and September 30, 2022, on April 5, 2023.
Due to high levels of previous infection and/or vaccination, Switzerland decides against recommending COVID-19 vaccines for citizens on April 10, 2023.
On April 14, 2023, a woman died from myocarditis following a COVID-19 vaccination, according to the coroner in Singapore.
Malaysian researchers identify 87 myocarditis cases within 21 days of COVID-19 vaccination among those vaccinated between February 1, 2021 and February 28, 2022 on April 15, 2023.
On April 18, 2023, the FDA replaces the outdated Moderna and Pfizer vaccines with the updated bivalent shots, despite the fact that no clinical trial efficacy estimates are available.
On April 18, 2023, the United States government compensates two people for myocarditis caused by COVID-19 vaccines.
The FDA rejects a request to add the risk of sudden death to the labels of mRNA vaccines on April 18, 2023.
On April 19, 2023, CDC officials, including Dr. Shimabukuro, repeat lies about the safety of the COVID-19 vaccine.
On April 20, 2023, the CDC recommends that unvaccinated people receive a bivalent vaccine, and that some vaccinated people receive an additional shot.
April 24, 2023: After analyzing trial data, researchers conclude that mRNA COVID-19 vaccines had no effect on overall mortality.
May 10, 2023: Some myocarditis patients had LGE on cardiac MRIs performed 107 days after initial MRIs, according to US researchers.
COVID-19 public health emergency ends on May 11, 2023, but vaccines are still available under emergency authorization.
May 11, 2023: Swedish researchers report that 96 percent of cases of postvaccination myocarditis were correctly registered.
The majority of the remaining federal COVID-19 vaccine mandates expire on May 12, 2023.
May 22, 2023: The FDA declares that myocarditis meets the safety signal criteria in children aged 12 to 17.
Vaccine-injured people sue the federal government over Big Tech censorship on May 22, 2023.
On June 1, 2023, the United States government compensates a third party for myocarditis caused by the COVID-19 vaccination.
Johnson & Johnson’s COVID-19 vaccine is revoked by the FDA on June 1, 2023.
Sudden deaths caused by COVID-19 vaccination, South Korean researchers discover on June 2, 2023.
The CDC claims that no postvaccination deaths have been caused by myocarditis as of June 13, 2023.
South Korean researchers estimate 82 myocarditis per million third doses in those under the age of 19.
June 14, 2023: Seniors are not at increased risk of myocarditis following COVID-19 vaccination, according to an FDA review of surveillance data.
On June 15, 2023, the FDA estimates that each million Moderna primary series administered to people aged 18 to 25 will prevent 635 to 5,957 COVID-19 hospitalizations and result in an excess of 68 to 241 myocarditis cases.
Researchers report 139 postvaccination myocarditis cases across 29 centers in Spain from August 1, 2021, to March 10, 2022, with a 3-month follow-up showing a 12.7 percent incidence of adverse events and 1.4 percent mortality.
Moderna’s subclinical myocarditis study expires on June 30, 2023, without publication.
Australia stops reporting postvaccination myocarditis cases on July 17, 2023, claiming that rates have stabilized.
July 20, 2023: A prospective study finds that one in every 35 health care workers had signs of heart injury as a result of vaccination.
Long-term issues were discovered in a one-year followup, according to Hong Kong researchers.
Pfizer officials tell the Australian Senate on August 3, 2023, that they don’t know why the company’s vaccine causes heart inflammation.
Documents show that the CDC repeatedly advised people who experienced adverse events after vaccination to get additional shots on September 5, 2023.
On September 12, 2023, the CDC reports two cases of myocarditis or pericarditis following bivalent vaccination in VSD.
Data from the Centers for Disease Control and Prevention show that bivalent protection against hospitalization drops sharply within months of September 12, 2023.
On September 12, 2023, the CDC recommends new vaccines based on trial data from only 50 people.
